OakChart

Bristol-Myers Squibb Co

BMYHealthcare·Drug Manufacturers - General·USA·Large·NYSE·Nov 11 • 12:41 PM ET

61.97-0.83 (-1.33%)
2026-11-11 18:42 CET
Market cap
128,368.85 USD m
Revenue, TTM
50,049.00 USD m
Net income, TTM
9,243.00 USD m
Free cash flow, TTM
9,286.00 USD m
EPS diluted, TTM
4.51
P/E
13.73
Compare

Price

BMY against its 20, 50 and 200-day averages
2050200beat
55.0060.0065.0018.4M36.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BMYclose 61.9720-day 61.7650-day 62.08200-day 60.2561.9752w high

9.7% under the 52-week high of 68.64 on 19 Aug 2026. 52-week low 45.27 on 20 Nov 2025. Last 15 sessions, 9.2% high to low

Profile

BMY
52-week range, 71% of the way up
45.2668.64

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

IndexS&P 500, RUI
Employees32500
IPOJul 05, 1929
Beta0.19
ATR, 14d1.73
Rel volume0.44
Short float2.30%
Insider own0.32%
Inst own84.95%

Snapshot

6 groups

Valuation

IndexS&P 500, RUI
Market Cap126.66B
Enterprise Value158.89B
Income9.24B
Sales50.05B
Book/sh11.45
Cash/sh6.15
Dividend Est.2.54 (4.10%)
Dividend TTM2.52 (4.07%)
Dividend Ex-DateOct 02, 2026
Dividend Gr. 3/5Y4.37% 6.24%
Payout71.98%
Employees32500
IPOJul 05, 1929

Ratios

P/E13.73
Forward P/E9.25
PEG-
P/S2.53
P/B5.41
P/C10.07
P/FCF13.64
EV/EBITDA8.20
EV/Sales3.17
Quick Ratio1.44
Current Ratio1.59
Debt/Eq1.91
LT Debt/Eq1.86
Option/ShortYes / Yes

Earnings

EPS (ttm)4.51
EPS next Y6.70
EPS next Q1.50
EPS this Y4.78%
EPS next Y3.97%
EPS next 5Y-4.86%
EPS past 3/5Y5.47% -
Sales past 3/5Y1.45% 2.54%
EPS Y/Y TTM52.55%
Sales Y/Y TTM4.19%
EPS Q/Q-2.44%
Sales Q/Q6.99%
EarningsOct 29 BMO
EPS/Sales Surpr.22.86% 2.72%

Ownership

Insider Own0.32%
Insider Trans-0.16%
Inst Own84.95%
Inst Trans1.06%
ROA9.96%
ROE44.06%
ROIC13.80%
Gross Margin66.32%
Oper. Margin32.93%
Profit Margin18.47%
SMA200.34%
SMA50-0.18%
SMA2002.84%
Trades-

Technical

Shs Outstand2.04B
Shs Float2.04B
Short Float2.30%
Short Ratio4.30
Short Interest46.85M
52W High68.64 -9.72%
52W Low45.26 36.89%
Volatility2.95% 2.75%
ATR (14)1.73
RSI (14)50.37
Beta0.19
Rel Volume0.44
Avg Volume10.90M
Volume2,482,268

Performance

Perf Week-3.47%
Perf Month9.34%
Perf Quarter-4.15%
Perf Half Y9.89%
Perf YTD14.88%
Perf Year27.19%
Perf 3Y22.44%
Perf 5Y4.69%
Perf 10Y9.93%
Recom2.48
Target Price65.04
Prev Close62.80
Price61.97
Change %-1.33%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 05, 2026DowngradeLLeerink PartnersOutperform → Market Perform$59-4.8%
Aug 05, 2026UpgradeAArgusHold → Buy$75+21.0%
Feb 25, 2026InitiatedRRBC Capital MktsSector Perform$60-3.2%
Feb 20, 2026InitiatedBBarclaysOverweight$75+21.0%
Jan 07, 2026UpgradeUUBSNeutral → Buy$65+4.9%
Dec 15, 2025UpgradeBBofA SecuritiesNeutral → Buy$61-1.6%
Dec 12, 2025UpgradeGGuggenheimNeutral → Buy$62+0.1%
Nov 13, 2025InitiatedBScotiabankSector Perform$45-27.4%
Aug 05, 2025DowngradeDDaiwa SecuritiesOutperform → Neutral$42-32.2%
Apr 22, 2025InitiatedPPiper SandlerOverweight

Peers

Mkt cap
TickerCompanyMkt cap
MRKMerck & Co Inc359.83B
PFEPfizer Inc166.69B
AZNAstrazeneca plc286.28B
NVSNovartis AG ADR291.83B
ABBVAbbvie Inc515.56B
AMGNAMGEN Inc250.20B
GILDGilead Sciences Inc209.85B
JNJJohnson & Johnson668.03B
GSKGSK Plc ADR100.42B
LLYLilly(Eli) & Co1341.67B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Haller Julia ADirectorNov 05 '26Sale63.313,800240,57830,279Nov 06 04:25 PM
Julia A Haller GottschDirectorNov 05 '26Proposed Sale65.793,800250,000Nov 06 01:30 PM
Lenkowsky AdamEVP, Chief Commercial OfficerNov 03 '26Option Exercise0.007,522027,228Nov 04 04:49 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerNov 01 '26Option Exercise0.002,964024,415Nov 03 04:30 PM
Shanahan KarinEVP, Chief Supply Chain & OpsNov 01 '26Option Exercise0.006,281032,169Nov 03 04:27 PM
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Nov 01 '26Option Exercise0.006,281036,642Nov 03 04:18 PM
Gallman CariEVP, General CounselOct 02 '26Option Exercise0.004,559018,208Oct 05 04:18 PM
Massacesi CristianEVP,Chief Med Offr,Head of DevSep 09 '26Sale64.576,249403,49818,748Sep 10 04:37 PM
Massacesi CristianOfficerSep 09 '26Proposed Sale64.576,249403,498Sep 09 10:27 AM
Short Bartie WendyEVP, Corporate AffairsSep 01 '26Option Exercise66.921,23682,71313,317Sep 03 04:12 PM
Holzer Phil MSVP and ControllerAug 25 '26Sale67.5050033,75016,862Aug 26 04:17 PM
Holzer Phil MOfficerAug 25 '26Proposed Sale67.5050033,750Aug 25 11:03 AM
Massacesi CristianEVP,Chief Med Offr,Head of DevAug 01 '26Option Exercise0.0051,172051,172Aug 04 04:10 PM
Gallman CariEVP, General CounselAug 01 '26Option Exercise0.001,061014,192Aug 04 04:07 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
SCHDSchwab US Dividend Equity ETFAUM: 122.69B
VOOVanguard S&P 500 ETFAUM: 1054.75B
IVViShares Core S&P 500 ETFAUM: 871.38B
SPYSPDR S&P 500 ETF TrustAUM: 793.23B
VTVVanguard Morningstar Value ETFAUM: 196.23B
XLVState Street Health Care Select Sector SPDR ETFAUM: 50.35B
VYMVanguard High Dividend Yield Indx ETFAUM: 83.15B
HDViShares Core High Dividend ETFAUM: 16.41B
HDViShares Core High Dividend ETFAUM: 16.41B

News

latest 14 of 103
  • Up 42% since January: Why Merck is defeating the patent cliff (Investing.com)
  • While pharma peers stumble, AbbVie defeated the patent cliff (Investing.com)
  • Trump's Plan to Lower Drug Prices in U.S. Is Leading to Fewer New Drugs in Europe (The Wall Street Journal)
  • Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions (Business Wire)
  • TEM Stock Jumps On Upbeat Revenue, Raised Outlook Cathie Woods ARK Buys Over 154K Shares Ahead Of Earnings (Stocktwits)
  • Loading…
  • Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer (Barrons.com)
  • AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock (Barrons.com)
  • Eli Lillys tirzepatide outperforms big pharma companies in Q3 (Pharmaceutical Technology)
  • Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue (Bloomberg)
  • Bristol Myers Still Confident in Autoimmune Therapy After Patient Death (The Wall Street Journal)
  • Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook (InvestorsHub)
  • Anthropic Announced New Achievements in Drug Research and Lab Work. An Expert Says AI is 'Changing the Medical Field.' (International Business Times)
  • Bristol Myers Beats And Raises For A Third Straight Quarter, But Slowing Growth Drivers And The Eliquis Cliff Keep The Debate Alive (Earnings Whispers)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-291.3501.0991.05013,06912,72318
2026Q22026-07-302.0401.5971.62012,97311,73923
2026Q12026-04-301.5801.4241.30811,48910,92724
2025Q42026-02-051.2601.2260.53312,50212,28021
2025Q32025-10-301.6301.5181.07912,22211,85020
2025Q22025-07-311.4601.0910.64312,26911,44418
2025Q12025-04-241.8001.4951.20411,20110,69519
2024Q42025-02-061.6701.4630.03512,34211,56720
2024Q32024-10-311.8001.4940.59611,89211,26419
2024Q22024-07-262.0701.6200.82812,20111,53920
2024Q12024-04-25-4.400-4.412-5.88811,86511,48217
2023Q42024-02-021.7001.5540.86711,47711,19218
2023Q32023-10-262.0001.7640.93410,96610,95520
2023Q22023-07-271.7501.9620.98611,22611,76520
2023Q12023-04-272.0501.9721.07111,33711,49619
2022Q42023-02-021.8201.7270.95211,40611,18619

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY4.6904.6532.00926,14525,325
2020FY6.4406.401-3.99342,51842,200
2021FY7.5107.4703.11546,38546,456
2022FY7.7007.3872.94846,15945,919
2023FY7.5107.3833.86245,00644,710
2024FY1.1500.915-4.41448,30047,513
2025FY6.1506.1143.46048,19447,990
2026FY-6.444--50,174
2027FY-6.699--48,827
2028FY-5.296--40,379
2029FY-4.847--37,246
2030FY-4.929--37,089

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06195912,66212,42013,027
2026Q4S2026-11-041941012,65412,42013,027
2026Q4S2026-11-021941012,65212,42013,027
2026Q4S2026-10-291941012,65612,42013,027
2026Q4S2026-10-23196412,71012,20813,045
2026Q4S2026-10-20196412,71612,20813,045
2026Q4S2026-10-19195412,69412,20813,045
2026Q4S2026-10-16195412,69412,20813,045
2026Q4S2026-10-14194412,67312,20813,006
2026Q4S2026-10-13196412,67312,20813,006
2026Q4S2026-10-121916312,68412,20813,006
2026Q4S2026-10-091916312,66512,13813,006
2026Q4S2026-10-081918112,67512,13813,006
2026Q4S2026-10-071918112,66812,13813,006

Estimate history

EPS, annual0.613.0062.009-3.9933.1152.9483.862-4.4143.464.5131
Period201720182019202020212022202320242025TTM
EPS, quarterly0.5960.0351.2040.6431.0790.5331.3081.621.053
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual20776225612614542518463854615945006483004819450049
Period201720182019202020212022202320242025TTM
Sales, quarterly118921234211201122691222212502114891298213076
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1625162422282244217620982021202920362044
Period201720182019202020212022202320242025MRQ
Shares, quarterly202820292035203520362036204220432044
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue50,049.0048,194.0048,300.0045,006.0046,159.0046,385.0042,518.0026,145.0022,561.00
Cost of Goods Sold Incl. D&A16,859.0016,436.0020,868.0019,649.0019,669.0019,624.0020,818.008,895.006,486.00
Gross Profit33,190.0031,758.0027,432.0025,357.0026,490.0026,761.0021,700.0017,250.0016,075.00
Selling, General and Administrative Excl. Other16,709.0016,641.0017,774.0016,885.0017,219.0017,221.0017,208.0010,811.009,681.00
Research and Development9,479.009,492.009,782.009,207.009,411.009,533.009,557.005,949.005,131.00
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income16,481.0015,117.009,658.008,472.009,271.009,540.004,492.006,439.006,394.00
Interest Expense1,653.001,891.001,947.001,166.001,232.001,334.001,420.00656.00183.00
Unusual Expense5,470.006,464.0018,154.001,056.001,780.002,749.0012,878.002,631.001,617.00
Net Income Before Taxes11,331.009,328.00-8,379.008,440.007,713.008,098.00-6,871.004,975.005,968.00
Income Taxes2,089.002,272.00554.00400.001,368.001,084.002,124.001,515.001,021.00
Consolidated Net Income9,242.007,056.00-8,933.008,040.006,345.007,014.00-8,995.003,460.004,947.00
Net Income From Continuing Operations9,243.007,054.00-8,948.008,025.006,327.006,994.00-9,015.003,439.004,920.00
Net Income9,243.007,054.00-8,948.008,025.006,327.006,994.00-9,015.003,439.004,920.00
EPS (Recurring)6.375.681.854.223.533.97-0.003.083.70
EPS (Basic, Before Extraordinaries)4.533.47-4.413.882.973.15-3.992.023.01
EPS (Diluted)4.513.46-4.413.862.953.12-3.992.013.01
EBITDA19,376.0019,238.0019,309.0018,283.0019,558.0020,299.0014,978.008,248.007,097.00
Non-Operating Income (Expense)1,972.002,566.002,064.002,190.001,454.002,641.002,935.001,823.001,374.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense437.00438.00399.00413.00366.00463.00621.00354.00180.00
Price To Earnings Ratio13.9213.92-13.0123.4519.99-29.2217.19
Price To Sales Ratio2.562.282.372.373.353.023.294.203.77
Gross Margin66.3265.9056.8056.3457.3957.6951.0465.9871.25
Operating Margin32.9331.3720.0018.8220.0820.5710.5624.6328.34
Net Margin18.4714.64-18.5317.8313.7115.08-21.2013.1521.81
Shares Outstanding2,044.002,036.002,029.002,021.002,098.002,176.002,244.002,228.001,624.00
Market Capitalization128,368.85128,368.85114,713.86104,403.54152,977.21138,395.18140,172.29104,584.1384,841.76

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q32025Q22025Q1
Total Revenue13,076.0012,982.0011,489.0012,502.0012,222.0012,222.0012,269.0011,201.00
Cost of Goods Sold Incl. D&A4,604.004,161.003,873.004,221.004,156.003,313.004,199.003,861.00
Gross Profit8,472.008,821.007,616.008,281.008,066.008,909.008,070.007,340.00
Selling, General and Administrative Excl. Other4,063.004,142.003,855.004,649.004,221.004,221.003,953.003,819.00
Research and Development2,364.002,316.002,238.002,561.002,433.002,433.002,262.002,236.00
Other Operating Expense0.000.000.000.000.00831.000.000.00
Operating Income4,409.004,679.003,761.003,632.003,845.003,857.004,117.003,521.00
Interest Expense403.00407.00411.00432.00480.00480.00485.00494.00
Unusual Expense1,872.00663.00468.002,467.001,078.001,127.002,638.00523.00
Net Income Before Taxes2,536.004,086.003,239.001,470.003,114.003,114.001,773.002,971.00
Income Taxes374.00770.00561.00384.00919.00919.00460.00509.00
Consolidated Net Income2,162.003,316.002,678.001,086.002,195.002,195.001,313.002,462.00
Net Income From Continuing Operations2,162.003,317.002,677.001,087.002,201.002,201.001,310.002,456.00
Net Income2,162.003,317.002,677.001,087.002,201.002,201.001,310.002,456.00
EPS (Recurring)1.691.851.471.381.45-1.551.38
EPS (Basic, Before Extraordinaries)1.061.621.310.531.081.080.641.21
EPS (Diluted)1.051.621.310.531.081.080.641.20
EBITDA5,051.005,289.004,372.004,664.004,871.00-5,146.004,549.00
Non-Operating Income (Expense)402.00476.00357.00737.00827.00865.00779.00466.00
Other After Tax Adjustments0.000.000.000.000.00-0.000.00
Stock Option Compensation Expense108.00107.00116.00106.00110.00-109.00114.00
Price To Earnings Ratio13.9216.1717.5418.2118.2017.4817.38-
Price To Sales Ratio2.562.402.562.281.912.061.982.61
Gross Margin64.7967.9566.2966.2466.0072.8965.7865.53
Operating Margin33.7236.0432.7429.0531.4631.5633.5631.43
Net Margin16.5325.5523.308.6918.0118.0110.6821.93
Shares Outstanding2,044.002,043.002,042.002,036.002,036.00-2,035.002,035.00
Market Capitalization128,368.85117,664.07123,511.91109,808.3591,798.3488,139.3194,203.85124,100.01

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments10,673.0010,859.0012,335.009,401.0017,361.0016,539.0015,393.008,884.006,812.00
Short Term Receivables14,526.0014,424.0015,264.0013,937.0012,516.0010,300.008,439.005,782.005,609.00
Inventories2,690.002,557.002,662.002,339.002,095.002,074.004,293.001,195.001,166.00
Other Current Assets1,501.001,940.001,509.001,596.001,290.001,279.001,229.001,299.001,267.00
Total Current Assets29,390.0029,780.0031,770.0027,273.0033,262.0030,192.0029,354.0017,160.0014,854.00
Net Property, Plant & Equipment9,125.008,360.008,036.007,475.006,968.006,745.006,956.005,027.005,001.00
Total Investments and Advances2,492.002,056.002,063.002,241.002,910.004,847.004,562.001,889.002,546.00
Long-Term Note Receivable15.00452.00436.00----19.000.00
Intangible Assets40,857.0045,026.0048,241.0057,008.0063,029.0073,790.0086,457.007,629.008,073.00
Deferred Tax Assets5,378.004,236.002,768.001,344.001,439.001,161.00510.001,371.001,610.00
Other Assets2,781.002,693.001,845.001,479.001,706.001,746.002,105.001,891.001,467.00
Total Assets90,038.0092,603.0095,159.0096,820.00109,314.00118,481.00129,944.0034,986.0033,551.00
Short Term Debt Incl. Current Port. of LT Debt2,463.002,227.003,281.004,400.005,117.002,504.003,479.001,703.00987.00
Accounts Payable3,575.003,602.003,259.003,040.002,949.002,713.002,445.001,892.002,248.00
Income Tax Payable979.001,514.001,371.00942.00754.00647.001,517.00398.00231.00
Other Current Liabilities16,400.0016,431.0014,351.0013,508.0013,048.0013,216.0010,863.006,661.006,097.00
Total Current Liabilities23,417.0023,774.0022,262.0021,890.0021,868.0019,080.0018,304.0010,654.009,563.00
Long Term Debt44,676.0048,973.0038,183.0036,317.0040,479.0049,169.0044,059.005,646.006,975.00
Provision for Risks Charges330.00400.00480.00402.00654.00899.00725.000.000.00
Deferred Tax Liabilities222.00369.00338.002,166.004,501.005,407.006,454.00--
Other Liabilities2,887.002,699.004,411.004,927.005,806.006,044.008,704.004,559.005,166.00
Total Liabilities71,532.0076,215.0065,674.0065,702.0073,308.0080,599.0078,246.0020,859.0021,704.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity18,473.0016,335.0029,430.0031,061.0035,946.0037,822.0051,598.0014,031.0011,741.00
Total Shareholders Equity18,473.0016,335.0029,430.0031,061.0035,946.0037,822.0051,598.0014,031.0011,741.00
Accumulated Minority Interest33.0053.0055.0057.0060.0060.00100.0096.00106.00
Total Equity18,506.0016,388.0029,485.0031,118.0036,006.0037,882.0051,698.0014,127.0011,847.00
Total Liabilities & Stockholders Equity90,038.0092,603.0095,159.0096,820.00109,314.00118,481.00129,944.0034,986.0033,551.00
Book Value Per Share9.078.0514.5614.8116.5216.8523.168.647.23
Tangible Book Value Per Share-10.99-14.14-9.31-12.37-12.45-16.03-15.653.942.26
Full-Time Employees32,50034,10034,10034,30032,20030,25030,00023,30023,700
Price to Book Ratio5.486.693.604.683.773.682.776.026.78
Return on Assets7.72-9.538.366.146.14-7.264.1714.362.99
Return on Equity40.53-39.1026.5318.8818.96-20.1610.4838.187.21
Return on Invested Capital11.17-13.7011.879.399.15-10.363.6025.005.38
Quick Ratio1.141.151.311.141.431.471.371.501.43
Current Ratio1.261.251.431.251.521.581.601.611.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income9,241.007,055.00-8,933.008,040.006,345.007,014.00-8,995.003,460.004,947.00
Depreciation2,791.004,011.009,600.009,760.0010,276.0010,686.0010,380.001,746.00637.00
Other Funds (Non Cash)4,475.004,510.0015,802.001,262.001,412.001,153.0010,701.00720.0094.00
Funds from Operations15,571.0014,611.0014,380.0015,774.0015,295.0017,460.0013,069.005,002.005,764.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4,919.00-455.00810.00-1,914.00-2,229.00-1,253.00983.003,065.00176.00
Income Taxes Payable-464.00-4.00-1,260.00-603.00-1,423.00-1,063.00-2,305.00907.00162.00
Cash from Operating Activities10,652.0014,156.0015,190.0013,860.0013,066.0016,207.0014,052.008,067.005,940.00
Capital Expenditures-1,366.00-1,311.00-1,248.00-1,209.00-1,118.00-973.00-753.00-836.00-951.00
Net Assets From Acquisitions-2,975.00-3,944.00-21,821.00-1,169.00-4,286.00-1,610.00-13,084.00-24,634.00-1,246.00
Sale of Fixed Assets and Businesses791.001,071.001,099.00909.001,305.00748.00870.0015,852.001,249.00
Purchase or Sale of Investments-1,757.0052.00618.00-826.003,037.001,297.002,108.00-152.0074.00
Purchase of Investments-4,616.00-2,000.00-769.00-1,774.00-3,592.00-5,478.00-4,172.00-3,961.00-2,305.00
Sale Or Maturity of Investments2,859.002,052.001,387.00948.006,629.006,775.006,280.003,809.002,379.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-5,307.00-4,132.00-21,352.00-2,295.00-1,062.00-538.00-10,859.00-9,770.00-874.00
Cash Dividends Paid-5,119.00-5,045.00-4,863.00-4,744.00-4,634.00-4,396.00-4,075.00-2,679.00-2,613.00
Change in Capital Stock0.000.000.00-5,155.00-8,001.00-6,287.00-1,546.00-7,300.00-320.00
Repurchase of Common Pref Stock0.000.000.00-5,155.00-8,001.00-6,287.00-1,546.00-7,300.00-320.00
Sale of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-6,264.00-5,175.0010,096.00456.00-5,311.00-6,182.003,928.0017,653.00-548.00
Change in Long Term Debt-6,048.00-5,200.0010,010.00576.00-5,505.00-6,022.004,195.0017,522.00-5.00
Issuance of Long Term Debt5,740.005,740.0012,883.004,455.005,926.000.006,945.0026,778.000.00
Reduction of Long Term Debt-11,788.00-10,940.00-2,873.00-3,879.00-11,431.00-6,022.00-2,750.00-9,256.00-5.00
Net Financing Active Other Cash Flow-58.00-128.00-106.0027.00984.00641.00542.00-53.00-54.00
Other Financing Activities Uses-58.00-128.00-106.000.000.000.000.00-53.00-54.00
Cash from Financing Activities-11,441.00-10,348.005,127.00-9,416.00-16,962.00-16,224.00-1,151.007,621.00-3,535.00
Exchange Rate Effect-56.00195.00-137.0045.00-33.00-102.00111.00-9.00-41.00
Net Change in Cash-6,152.00-129.00-1,172.002,194.00-4,991.00-657.002,153.005,909.001,490.00
Free Cash Flow9,286.0012,845.0013,942.0012,651.0011,948.0015,234.0013,299.007,231.004,989.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow30.7414.1012.6313.4821.1112.9215.1824.1435.81
Deferred Taxes & Investment Tax Credit--965.00-2,089.00-3,288.00-2,738.00-1,393.00983.00-924.0086.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q3
Cash & Short Term Investments12,581.0011,067.0010,486.0010,673.0016,502.0016,502.00
Short Term Receivables12,850.0013,000.0012,082.0014,526.0014,616.00-
Inventories2,704.002,737.002,756.002,690.002,758.00-
Other Current Assets1,633.001,775.001,884.001,501.001,754.00-
Total Current Assets29,767.0028,579.0027,208.0029,390.0035,630.00-
Net Property, Plant & Equipment9,451.009,277.009,186.009,125.008,953.00-
Total Investments and Advances2,320.002,387.002,241.002,492.002,342.00406.00
Intangible Assets38,671.0039,127.0039,984.0040,857.0042,210.00-
Deferred Tax Assets5,884.005,362.005,176.005,378.004,961.00-
Other Assets2,677.002,903.002,680.002,781.002,777.00-
Total Assets88,772.0087,634.0086,476.0090,038.0096,889.00-
Short Term Debt Incl. Current Port. of LT Debt1,248.001,234.002,507.002,463.004,723.004,509.00
Accounts Payable4,628.004,158.004,234.003,575.004,288.00-
Income Tax Payable727.00806.00909.00979.001,022.00-
Other Current Liabilities12,150.0012,461.0011,508.0016,400.0018,103.00-
Total Current Liabilities18,753.0018,659.0019,158.0023,417.0028,136.00-
Long Term Debt43,562.0043,819.0043,922.0044,676.0046,318.0044,469.00
Provision for Risks Charges299.00307.00317.00330.00393.00-
Deferred Tax Liabilities228.00222.00211.00222.00225.00-
Other Liabilities2,526.002,308.002,765.002,887.003,217.00-
Total Liabilities65,368.0065,315.0066,373.0071,532.0078,289.00-
Non-Equity Reserves0.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity23,404.0022,319.0020,068.0018,473.0018,552.00-
Total Shareholders Equity23,404.0022,319.0020,068.0018,473.0018,552.00-
Accumulated Minority Interest0.000.0034.0033.0048.00-
Total Equity23,404.0022,319.0020,102.0018,506.0018,600.00-
Total Liabilities & Stockholders Equity88,772.0087,634.0086,475.0090,038.0096,889.00-
Book Value Per Share11.4510.929.839.079.11-
Tangible Book Value Per Share-7.47-8.23-9.75-10.99-11.62-
Full-Time Employees---32,500--
Price to Book Ratio5.485.866.685.925.265.05
Return on Assets9.9610.188.137.726.34-
Return on Equity44.0646.7038.8440.5333.84-
Return on Invested Capital3.235.024.181.723.39-
Quick Ratio1.441.381.281.141.17-
Current Ratio1.591.531.421.261.27-

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q3
Net Income2,162.003,316.002,678.001,085.002,195.00-
Depreciation626.00594.00594.00977.001,011.00-
Other Funds (Non Cash)1,710.00302.00505.001,958.00409.00-
Funds from Operations3,988.004,017.003,938.003,628.003,256.00-
Extraordinary Item0.000.000.000.000.00-
Changes in Working Capital193.00-624.00-2,834.00-1,654.003,055.00-
Income Taxes Payable195.00-522.00187.00-324.00887.00-
Cash from Operating Activities4,181.003,393.001,104.001,974.006,311.00-
Capital Expenditures-344.00-305.00-347.00-370.00-320.00-
Net Assets From Acquisitions-1,112.00-91.00-65.00-1,707.00-1,874.00-
Sale of Fixed Assets and Businesses-9.00209.00312.00279.00279.00-
Purchase or Sale of Investments-639.00-1,427.00-31.00340.00213.00-
Purchase of Investments-1,687.00-2,070.00-781.00-78.00-665.00-
Sale Or Maturity of Investments1,048.00643.00750.00418.00878.00-
Other Uses0.000.000.000.000.00-
Other Sources0.000.000.000.000.00-
Cash from Investing Activities-2,104.00-1,614.00-131.00-1,458.00-1,702.00-
Cash Dividends Paid-1,287.00-1,287.00-1,283.00-1,262.00-1,263.00-
Preferred Dividends (Cash Flow)0.000.000.000.000.00-
Change in Capital Stock0.000.000.000.000.00-
Repurchase of Common Pref Stock0.000.000.000.000.00-
Sale of Common Pref Stock0.000.000.000.000.00-
Proceedsfrom Stock Options0.000.000.000.000.00-
Issuance or Reduction of Debt, Net-1.00-1,350.00-179.00-4,734.00-224.00-
Change in Long Term Debt0.00-1,220.00-500.00-4,328.00-229.00-
Issuance of Long Term Debt0.000.000.005,740.000.00-
Reduction of Long Term Debt0.00-1,220.00-500.00-10,068.00-229.00-
Net Financing Active Other Cash Flow66.007.00-98.00-33.00-3.00-
Other Financing Activities Uses66.007.00-98.00-33.00-3.00-
Cash from Financing Activities-1,222.00-2,630.00-1,560.00-6,029.00-1,490.00-
Exchange Rate Effect-3.00-10.00-48.005.00-4.00-
Net Change in Cash852.00-861.00-635.00-5,508.003,115.00-
Free Cash Flow3,837.003,088.00757.001,604.005,991.00-
Price to Free Cash Flow30.7418.6018.1614.118.93-

Revenue breakdown

Abecma2024: 406.00M 2025: 427.00M
Abraxane2024: 875.00M 2025: 368.00M
Breyanzi2024: 747.00M 2025: 1.36B
Camzyos2024: 602.00M 2025: 1.07B
Cobenfy2024: 10.00M 2025: 155.00M
Consolidation, Policy2025: -1.00M
Eliquis2024: 13.33B 2025: 14.44B
Krazati2024: 126.00M 2025: 205.00M
Opdivo2024: 9.30B 2025: 10.05B
Opdivo Ovantig2025: 238.00M
Opdualag2024: 928.00M 2025: 1.19B
Orencia2024: 3.68B 2025: 3.71B
Other Growth Brands2024: 1.64B 2025: 1.92B
Other Legacy Brands2024: 925.00M 2025: 798.00M
Pomalyst/Imnovid2024: 3.55B 2025: 2.73B
Reblozyl2024: 1.77B 2025: 2.33B
Revlimid2024: 5.77B 2025: 2.95B
Sotyktu2024: 246.00M 2025: 291.00M
Sprycel2024: 1.29B 2025: 493.00M
Yervoy2024: 2.53B 2025: 2.90B
Zeposia2024: 566.00M 2025: 577.00M
Non-US2024: 13.20B 2025: 13.83B
Other regions2024: 996.00M 2025: 1.09B
United States2024: 34.11B 2025: 33.28B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.30%46.8M2037.6M11.55M
2026-10-152.45%49.9M2036.2M11.54M
2026-09-302.25%45.8M2036.3M11.02M
2026-09-152.06%42.0M2036.3M11.14M
2026-08-312.16%44.1M2036.2M11.88M
2026-08-142.25%45.9M2036.2M12.37M
2026-07-312.57%52.3M2036.2M11.92M
2026-07-152.21%44.9M2035.6M11.67M
2026-06-301.99%40.5M2035.6M11.51M
2026-06-151.95%39.6M2035.6M11.54M
2026-05-291.89%38.5M2035.6M11.52M
2026-05-151.80%36.7M2035.6M11.79M
2026-04-301.54%31.3M2036.7M12.49M
2026-04-151.59%32.4M2036.4M13.00M
2026-03-311.55%31.5M2032.7M13.56M
2026-03-131.47%29.9M2032.7M13.71M
2026-02-271.64%33.4M2032.7M14.24M
2026-02-131.56%31.7M2032.7M14.64M
2026-01-301.47%29.9M2032.1M14.59M
2026-01-151.82%37.0M2032.1M15.39M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call35.0026.2028.5027.006.9711.000.000.997-0.0220.000
call40.0021.2023.1022.075.18615.000.000.997-0.0220.000
call45.0016.2018.050.004.0410.000.000.996-0.0210.001
call47.0014.2015.8515.203.4004.000.000.995-0.0210.001
call48.0013.2514.7014.263.0477.001.000.995-0.0210.001
call49.0012.2013.7513.342.9215.001.000.994-0.0210.001
call50.0011.2512.8512.222.8445.002.000.994-0.0200.001
call51.0010.2511.9011.302.7074.002.000.994-0.0200.001
call52.009.2010.6010.112.2243.000.000.993-0.0200.001
call53.007.959.608.802.0517.000.000.992-0.0200.001
call54.006.958.607.941.8799.000.000.992-0.0190.001
call55.006.207.356.741.4624.001.000.978-0.0470.002
call56.005.206.405.821.3366.001.000.973-0.0500.003
call57.004.355.205.280.97520.000.000.964-0.0580.004
call58.003.354.404.361.02222.000.000.930-0.0930.006
call59.002.353.553.400.96147.000.000.862-0.1540.010
call60.001.552.222.540.5433170.000.815-0.1480.012
call61.000.851.361.130.4451256.000.665-0.2130.017
call62.000.490.700.600.3781,2578.000.491-0.2070.018
call63.000.200.290.230.3792,12139.000.338-0.2220.017
call64.000.080.100.080.3741,33215.000.193-0.1580.012
call65.000.020.040.020.40067185.000.112-0.1160.009
call66.000.010.020.020.44143971.000.091-0.1190.007
call67.000.000.030.010.5281,82111.000.040-0.0590.004
call68.000.000.150.010.6111330.000.021-0.0360.002
call69.000.000.150.010.69197.000.000.018-0.0350.002
call70.000.000.010.010.77648.001.000.016-0.0350.002
call71.000.000.010.060.77463.000.000.009-0.0200.001
call72.000.000.010.100.8417.000.000.008-0.0210.001
call73.000.000.030.110.76832.000.000.014-0.0270.002
call74.000.000.030.000.8270.000.000.013-0.0270.002
call75.000.000.020.020.8851.000.000.012-0.0270.002
call80.000.000.020.001.1550.000.000.010-0.0290.001
put35.000.000.010.022.7531.000.00-0.002-0.0240.000
put40.000.002.130.002.1700.000.00-0.003-0.0230.000
put45.000.000.750.081.6756.000.00-0.004-0.0230.001
put47.000.000.750.001.4660.000.00-0.005-0.0230.001
put48.000.000.750.101.3655.000.00-0.005-0.0220.001
put49.000.000.750.081.26530.000.00-0.005-0.0220.001
put50.000.000.750.061.16620.000.00-0.006-0.0220.001
put51.000.000.750.061.07030.000.00-0.006-0.0220.001
put52.000.000.750.130.97316.000.00-0.007-0.0210.001
put53.000.000.750.100.87822.000.00-0.007-0.0210.001
put54.000.000.010.010.7182160.00-0.008-0.0150.001
put55.000.010.030.010.8091117.00-0.021-0.0480.002
put56.000.000.350.030.7013,1550.00-0.027-0.0510.003
put57.000.000.030.010.5961,4800.00-0.037-0.0590.004
put58.000.010.050.040.5194,0402,105-0.068-0.0920.006
put59.000.050.090.080.5042,08349.00-0.139-0.1580.010
put60.000.150.190.170.4575,98668.00-0.181-0.1460.012
put61.000.260.600.460.5542483.00-0.334-0.2130.017
put62.000.551.000.850.5322,1637.00-0.504-0.2140.018
put63.001.251.951.470.7383222.00-0.662-0.2220.017
put64.002.062.662.700.75427.003.00-0.807-0.1580.012
put65.002.703.652.950.9111180.00-0.895-0.1070.008
put66.003.705.402.151.5562.000.00-0.910-0.1180.007
put67.004.605.855.401.3431.000.00-0.960-0.0590.004
put68.005.856.706.331.3661.000.00-0.987-0.0200.001
put69.006.857.650.001.4530.000.00-0.989-0.0190.001
put70.007.708.908.381.7871.000.00-0.990-0.0200.001
put71.008.7010.959.302.6681.000.00-0.991-0.0200.001
put72.009.6512.250.003.0140.000.00-0.992-0.0200.001
put73.0010.8013.2511.573.1500.001.00-0.992-0.0200.001
put74.0011.9513.4012.502.6700.001.00-0.993-0.0210.001
put75.0012.8014.7013.563.0140.002.00-0.993-0.0210.001
put80.0017.7520.2518.544.0000.002.00-0.994-0.0220.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13GSEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100240.58K1
2026-100000
2026-0900403.50K1
2026-080033.75K1
2026-070000
2026-060000
2026-050000
2026-04001.85M1
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.83%
VANGUARD CAPITAL MANAGEMENT LLC6.53%
STATE STREET CORP5.01%
JPMORGAN CHASE & CO3.51%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC3.31%
GEODE CAPITAL MANAGEMENT, LLC2.48%
VANGUARD PORTFOLIO MANAGEMENT LLC2.30%
NORGES BANK1.81%
BANK OF AMERICA CORP /DE/1.67%
PRICE T ROWE ASSOCIATES INC /MD/1.55%

Funds

Fund% owned
Capital Group Central Corporate Bond Fund3.97%
VANGUARD INTERMEDIATE-TERM CORPORATE BOND INDEX FUND3.56%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.17%
Schwab U.S. Dividend Equity ETF2.73%
VANGUARD 500 INDEX FUND2.59%
iShares Core S&P 500 ETF1.38%
American Funds Inflation Linked Bond Fund1.37%
Fidelity 500 Index Fund1.30%
SPDR S&P 500 ETF TRUST1.21%
Capital Group Core Bond ETF1.20%

OakChart. BMY. Cached 15 minutes.